Martin Shkreli Takes Aim At Capricor — Stock Sinks

Capricor Therapeutics shares plunged after former executive Martin Shkreli publicly named the company as a short and predicted the stock would fall to roughly $2, criticizing the HOPE-3/COPE-3 trial and raising safety and cell‑trafficking concerns about lead candidate deramiocel; the stock fell about 17.39% to $4.75 at the time of reporting. Management concurrently announced a scalable framework for loading therapeutic oligonucleotides into exosomes—positioning the platform for potential manufacturing scale-up—while Benzinga reported Capricor did not respond to requests for comment.

Analysis

Market structure: The immediate winners are short sellers and any counterparties providing borrow; losers are retail holders and other microcap exosome plays facing sentiment spillover. Expect higher borrow fees, wider spreads and reduced liquidity in CAPR for days–weeks, compressing pricing efficiency and increasing realized volatility; sector-wide option IV likely to reprice up 20–60 bps on headline contagion while fixed income and FX remain immaterial.

Risk assessment: Tail risks include an SEC inquiry, clinical hold, or corroborating safety data that could force a >70% repricing; opposite tail is a partnership or clear technical rebuttal that halves losses within 3–12 months. Near-term (days) risks are liquidity and borrow squeezes; short-term (weeks–months) hinge on trial/readout news and cash runway; long-term (quarters–years) depends on manufacturability/IP and partner deals. Hidden dependencies: third‑party manufacturing contracts, patent scope and indemnities, and the company’s ability to service borrow costs.

Trade implications: Short bias is appropriate but size and instrument matter — use equity short or 3–6 month puts to limit asymmetric downside from squeezes. Pair trades neutralize sector beta: short CAPR vs long XBI or a 50–150bp long in large-cap pharma (PFE/MRK) as safety. Options strategies should focus on buying puts for 1–3 months (tight stop) and a small, tactical long-dated call (9–12 months) as a binary recovery ticket.

Contrarian angles: Consensus ignores that the new oligonucleotide-loading framework could trigger a partnership/licensing process that re-rates equity in 6–18 months; the price reaction may be overdone by 30–60% if management proves reproducibility. Historical parallels show influencer-driven microcap selloffs often mean-revert after regulatory clarification within 3–12 months, but legal and operational execution risks can permanently impair value.

Key Decisions for Investors

• Establish a tactical 1.0–1.5% portfolio short in CAPR (equity) immediately; set profit target 30–50% and a hard stop-loss at 15% adverse movement; horizon 2–8 weeks unless new clinical/regulatory data extends timeline.
• Buy 3‑month CAPR put options sized 0.5% portfolio at ~30–50% OTM to cap downside while participating in continued headline risk; take profits at +100–200% or roll if catalyst extends beyond expiry.
• Execute a pair trade: short CAPR (notional 1%) vs long XBI (SPDR S&P Biotech ETF) 1.5% to neutralize sector beta; hold 1–3 months and reassess after next regulatory/clinical communication.
• Allocate 0.5–1.0% portfolio to a contrarian binary long: buy 9–12 month CAPR calls (LEAPS) 2–3x OTM to capture partnership or platform validation upside; cap exposure due to low probability/high upside.
• Reduce aggregate microcap biotech exposure by 2–4% and redeploy into large-cap pharma (e.g., PFE/MRK) for lower volatility and cash‑flow stability over the next 3–12 months.